

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC **SWAP**

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP (Cardiovascular Biomarkers): Study Design

Study Design: SWAP (Cardiovascular)


- **Background:** Open-label, randomized trial examining cardiovascular biomarkers in virologically suppressed patients switching from ZDV-3TC to TDF-FTC or ABC-3TC
- **Inclusion Criteria:**
 - Adults with HIV infection
 - Receiving cART that includes ZDV-3TC
 - Undetectable HIV RNA for ≥ 12 weeks
 - No previous use of ABC or TDF
 - HLA-B*5701-negative
 - No diabetes mellitus or untreated HTN
- **Treatment Arms:**
 - Switch ZDV-FTC to TDF-FTC
 - Switch ZDV-FTC to ABC-3TC

Switch ZDV-3TC to TDF-FTC
(n = 20)

Switch ZDV-3TC to ABC-3TC
(n = 20)


Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP (Cardiovascular Biomarkers): Results

Week 48: Change in Cardiovascular Biomarkers from Baseline



Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP (Cardiovascular Biomarkers): Results

Week 48: Change in Plasma Lipids from Baseline



Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP (Cardiovascular Biomarkers): Conclusions

Conclusion: “In patients randomized to abacavir-based HIV-treatment transient increases were seen in the plasma levels of E-selectin and sVCAM-1 compared with treatment with tenofovir, but no difference between study arms was found in other biomarkers associated with endothelial dysfunction, inflammation, or coagulation. The clinical significance of these findings is uncertain.”

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP (Bone and Renal Effects): Study Design

Study Design: SWAP (Bone and Renal)


- **Background:** Open-label, randomized trial examining bone and renal effects of switching ZDV-3TC to TDF-FTC- or ABC-3TC in virologically suppressed patients
- **Inclusion Criteria:**
 - Adults with HIV infection
 - Receiving cART that includes ZDV-3TC
 - Undetectable HIV RNA for ≥ 12 weeks
 - No previous use of ABC or TDF
 - HLA-B*5701-negative
 - No diabetes mellitus or untreated HTN
- **Treatment Arms:**
 - Switch ZDV-FTC to TDF-FTC
 - Switch ZDV-FTC to ABC-3TC

Switch ZDV-3TC to TDF-FTC
(n = 20)

Switch ZDV-3TC to ABC-3TC
(n = 20)

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP (Bone and Renal Effects): Study Design

Week 48: Change in Bone Mineral Density from Baseline



Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP (Bone and Renal Effects): Conclusions

Conclusion: “Switching to TDF/FTC-based therapy led to decreases in BMD and increases in bone turnover markers compared with ABC/3TC-based treatment. No major difference in renal function was observed.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

